Polytherapy with sodium channel-blocking antiepileptic drugs is associated with arrhythmogenic ST-T abnormality in patients with epilepsy 
Introduction
Brugada syndrome is associated with a risk of life-threatening arrhythmia that exhibits specific ST-T elevations in the precordial leads on surface electrocardiograms (ECGs) [1] . Although the precise mechanism of the Brugada-type ECG remains unclear, an imbalance in the ventricular action potential durations between the epi-and endocardial muscular layers is thought to be important [1] .
Brugada-type ECG can be exaggerated by the action of sodium channel blockers such as flecainide or pilsicainide as well as an increase in parasympathetic nervous tone [2] . The J-wave, elevation of the junctional point of the terminal part of the QRS complex and the ST segment on a surface ECG, has been historically considered a normal variant, but the relationship between J-wave and idiopathic ventricular fibrillation has been documented [3] [4] [5] [6] . The mechanism of the appearance of J-wave also remains unclear, but recent studies emphasized its association with a repolarization abnormality or a local ventricular conduction delay [7] . The appearance or exaggeration of J-wave is also provoked by calcium channel-blocking action, probably through a conduction delay or slight prolongation of the local action potential duration caused by a decreasing inward calcium current [7] . Antzelevitch et al. proposed a syndrome termed ''J-wave syndrome'' in which Brugada syndrome and J-wave manifestation are mechanistically linked abnormalities in the manifestation of transient outward current [7] .
Epilepsy can also be caused by an abnormal inward sodium current and outward potassium current in cerebral neurons [8] . Therefore, some antiepileptic drugs (AEDs) exhibit several ion channel effects to suppress abnormal bursts of cerebral neurons, which may influence the cardiac ion currents to some degree. Recent reports documented the appearance of Brugada-type ST elevation in surface 12-lead ECGs in cases of AED overdose with a sodium channel-blocking effect [9, 10] . However, little is known about ECG changes that occur at therapeutic AED doses. Thus, we retrospectively identified patients with epilepsy taking AEDs and evaluated the incidence of Brugada or J-wave-like ECG abnormality.
Methods

Study population
The study population consisted of 475 consecutive patients who were diagnosed with epilepsy and treated in the outpatient ward at Kitasato University Hospital between 2005 and 2013. A total of 355 patients without ECG recordings or who were not taking AEDs were excluded from the evaluation. The remaining 120 patients with ECG recordings who were taking AEDs were enrolled for the evaluation and their clinical background and clinical data including age, sex, family history, epilepsy phenotyping, cardiac risk factors (hypertension, dyslipidemia, diabetes mellitus), heart disease, serum examination data, AED details, and 12-lead ECGs were retrospectively analyzed (Fig. 1) . A serum examination was performed at the same time of the 12-lead ECG recording, but we could not evaluate more information because of this study's retrospective nature. All studies were performed under approval from the Clinical Studies and Ethics Committee of Kitasato University Hospital.
Recording and analysis of the 12-lead ECG
The 12-lead ECG was recorded using a standard technique at a paper speed of 25 mm/s and recording amplitude of 1 mV/mm during stable therapy consisting of AEDs. In selected cases in which the 12-lead ECG was recorded before AEDs were started, those ECGs were also analyzed. In the ECG recording, heart rate (HR), PQ interval, QRS duration, and QT interval were measured. Corrected QT (QTc) interval was calculated using Bazzett's formula (QTc = QT/RR 1/2 ) [11] . The 12-lead ECGs were recorded in the outpatient clinic for epilepsy in our institute and analyzed here. Brugada-type ST elevation was identified in the precordial ECG leads (V1-2) and classified into Type 1, 2, or 3 in accordance with the consensus report on Brugada syndrome. Specifically, Type 1: coved ST-segment elevation displaying high J-wave amplitude (!2 mm) followed by a negative T-wave; Type 2: saddleback ST-segment elevation (!2 mm), high take-off, and gradual descent ST-segment elevation (remaining !1 mm), followed by a positive or biphasic T-wave; and Type 3: a saddleback or coved appearance with an ST-segment elevation <1 mm (Fig. 2) [1]. J-wave was defined as junctional point elevation !0.1 mV above baseline associated with notching, positive J deflection inscribed on the S-wave, and/or slurring with a smooth transition from the QRS segment to the ST segment, and the appearance of the terminal part of the QRS complex in at least two contiguous leads on inferior (II, III, aV F ) or lateral (I, aV L , V 4 , V 5 , V 6 ) leads (Fig. 3 ) [7] . The ECGs were evaluated by cardiologists who were specialists in cardiac electrophysiology and blinded to the patients' other clinical parameters.
AED classification
We classified the four drug groups by pharmacological effects [12] [13] [14] [15] : (1) 
Clinical epilepsy phenotyping
Enrolled patients were classified into drug-resistant epilepsy and drug-responsive epilepsy in accordance with their clinical phenotypes [16] . 
Statistical analysis
The study population was classified into four groups in accordance with the presence or absence of Brugada-type ST elevation or J-wave-like ECG abnormality (Fig. 1) . The clinical parameters were compared between patients with and those without Brugada-type ST elevation or between patients with and those without J-wave-like ECG abnormality. The statistical analysis was performed with JMP 11.2 (SAS Institute, Cary, North Carolina, USA). Continuous variables were compared using Student's t test or the Mann-Whitney U test and are presented as mean AE standard deviation. Discontinuous variables were compared using the chi-square test and are presented as percentages. A p-value < 0.05 was considered statistically significant.
Results
Clinical characteristics
The clinical characteristics of the 120 patients are summarized in Table 1 . The age range was 16-88 years old (mean, 43 AE 16 years old) and the male:female ratio was 57:63. Prescribed AEDs were CBZ in 63, PHT in 43, LTG in five, ESM in zero, GBP in five, VA in 52, PB in 11, BZD in 36, ZNS in seven, and TPM in seven patients. Each serum drug concentration was checked in patients, but none of them exhibited a concentration higher than the therapeutic range. All ECG parameters, namely HR, PR interval, QRS duration, and QTc, were within the normal range. No patients had a family history of sudden death, but eight patients had a family history of epilepsy.
Brugada or J-wave-like ECG abnormality
Of the 120 patients, 15 (12.5%) exhibited Brugada-type ST elevation: Type 1, one (0.8%); Type 2, three (2.5%); and Type 3, 11 (9.2%). On the other hand, J-wave-like ECG abnormality was observed in 35 (29.2%) patients. Two patients exhibited both a Fig. 3 . Definition of J-wave. J-wave was defined as a junctional point elevation (>0.1 mV), notching, or slurring appearance of the terminal part of QRS complex in inferior (II, III, aVF) or lateral leads (I, aVL, V4-6). Fig. 2 . Classification of Brugada type ECG. Type 1: coved ST-segment elevation displaying high J-wave amplitude (!2 mm) followed by a negative T-wave; Type 2: saddleback ST-segment elevation (!2 mm), high take-off, and gradual descent ST-segment elevation (remaining ! 1 mm), followed by a positive or biphasic T-wave; and Type 3: a saddleback or coved appearance with an ST-segment elevation <1 mm. Table 1 Patients' clinical characteristics.
Total, n = 120
Demographic data Age (years) 43 AE 16 Sex, male, n (%) 57 (48)
Family history
Family history of sudden death, n (%) 0 (0) Family history of epilepsy, n (%) 8
Cardiac morbidity
Epilepsy phenotyping Drug resistant epilepsy, n (%) 74 (62) Drug responsive epilepsy, n (%) 46 (38) Type 3 Brugada-type ST elevation and a J-wave-like ECG abnormality. The remaining 72 patients (60.0%) did not show an ST-T or QRS abnormality (Fig. 1) . In the present study, no patients experienced any spontaneous serious arryhythmic events. Table 2 compares patients with and without Brugada-type ST elevation (15 vs. 105 patients). Age, sex, family history, cardiac morbidity, epilepsy phenotyping, ECG parameters, blood examination, serum concentration, and AED use (CBZ, LTG, ESM, GBP, VA, PB, BZD, ZNS, TPM) were not significantly different between the two patient groups. However, PHT was used in a higher percentage of patients with Brugada-type ST elevation than in those without it (p = 0.001). Polytherapy with sodium channel-blocking AEDs (CBZ, PHT, LTG) was more frequently observed in patients with Brugadatype ST elevation (p = 0.048). Table 3 compares patients with and without a J-wave-like ECG abnormality (35 vs. 85). Similar to the comparison above, age, sex, family history, cardiac morbidity, epilepsy phenotyping, most of the ECG parameters, blood examination, and serum concentration and AED use (PHT, LTG, ESM, GBP, VA, PB, BZD, ZNS, TPM) were not significantly different between the two patient groups. However, CBZ was used in a lower percentage of patients with a J-wave-like ECG abnormality than those without it (p = 0.031). Additionally, QTc was shorter in patients with a J-wave-like ECG abnormality than in those without it (402 AE 25 ms vs. 413 AE 23 ms, respectively; p = 0.021). Contrary to the Brugada-type ECG changes, polytherapy with sodium channel-blocking AEDs was used in a lower percentage of patients with a J-wave-like ECG abnormality than those without it (p = 0.049).
Comparison of patients with and without ECG abnormality
ECG change after AED use
Because this was a retrospective observation study, the 12-lead ECG before AED start was available in only two patients. The ECG traces are presented in Fig. 4 . In a 64-year-old woman, the premedication ECG did not show a Brugada-type ST elevation, whereas the post-medication ECG did (Type 2) (Case 1). In a 59-year-old man, the ECG showed a J-wave-like ECG abnormality even before the start of VA, and the degree of the junctional point elevation was unchanged after the medication was started (Case 2). 
Discussion
First, the incidence of Brugada (12.5%) or J-wave-like ECG abnormality (29.2%) was high in the population in this study. Second, the use of PHT and polytherapy with sodium channelblocking AEDs were associated with patients with Brugada-type ST elevation. Third, contrary to the findings in Brugada-type ST elevation, the use of CBZ prescription and polytherapy with sodium channel-blocking AEDs were not associated with patients with J-wave-like ECG abnormality.
Incidence of Brugada or J-wave-like ECG abnormality in patients with epilepsy using AEDs
Previous reports have documented that the prevalence of Brugada-type ST elevation was 0.10-0.15% [17] [18] [19] and that of J-wave-like ECG abnormality was 3.3-12.9% [3] [4] [5] 20] in the general population without any structural heart diseases. In this study, Brugada-type ST elevation was observed in 15/120 (12.5%) patients and J-wave-like ECG abnormality was found in 35/120 (29.2%) patients with epilepsy taking AEDs. These rates are higher than those in the general population [3] [4] [5] [17] [18] [19] [20] . Lamberts et al. reported that the prevalence of Brugada-type ST elevation in patients with drug-resistant epilepsy was 2% [21] . However, in this study, the prevalence of Brugada-type ST elevation was higher. Such a difference might be related to racial differences. Brugada-type ST elevation is more frequently seen in Asian populations than in European populations.
The incidence of sudden cardiac death is reportedly two-to three-fold higher in patients with epilepsy than in the general population [22] ; in epilepsy itself, with the abnormality in sodium and potassium channels in cerebral neurons, there may be a similar background of sodium channel abnormality in cardiac myocytes. Parisi et al. reported that the SCN5A mutation was associated with coexisting Brugada syndrome and epilepsy [23] . The genetic mechanism concerning sodium channels might underlie J-wave syndrome and epilepsy [23, 24] . Polytherapy with sodium channelblocking AEDs was associated with Brugada-type ST elevation. We could not evaluate the 12-lead ECGs of patients with epilepsy and Brugada and a J-wave-like ECG abnormality before the start of AEDs, so the influence of epilepsy itself as the basic disease and AED use as the modulator cannot be separated. 
19 (54) In the present study, no patients experienced any spontaneous serious arryhythmic events, so we could not determine whether Brugada and a J-wave-like ECG abnormality during AED therapy would be a serious sign of sudden unexpected death in epilepsy. It was reported that the incidence of sudden unexpected death in epilepsy was 0.7 per 1000 person years [25] . Our study population was limited, so we emphasize the importance of future observations of patients with epilepsy.
Ion channel blockers may affect for not only the nervous system but also other systematic ion channels in other organs. As such, we must pay attention to drug side effect due to unexpected effects on other organs. Routine ECG evaluations in people with epilepsy may be important in their choice of AED therapy [21] . Additionally, such routine work may help prevent sudden cardiac death, and we hope that this and other reports will help improve the safety of antiepileptic therapy.
Effects of AEDs on ECG abnormalities
Brugada-type ST elevation and/or J-wave-like ECG abnormalities were more frequently observed in males than in females [5, [17] [18] [19] . In this study, the comparisons of clinical data between patients with and without such ECG abnormalities did not show any sex-based differences. However, there were differences in the use of some AEDs and polytherapy with sodium channel-blocking AEDs. Theoretically, sodium and calcium channel blockers are expected to shorten the action potential duration of cardiac myocytes and suppress the activation conduction by suppressing cationic current participating depolarization [26] . However, in Brugada syndrome, the effect of a sodium channel blocker such as ajmaline appears differently in epi-and endocardial myocytes, and this imbalanced effect is thought to exaggerate the ST elevation in the precordial leads [7] . In contrast, several reports have documented that a sodium channel blocker such as ajmaline might not affect the J-wave, but the mechanism behind this is unclear. These results appear consistent with those of previous reports [27] [28] [29] .
Difference in QTc in patients with and without J-wave-like ECG abnormality
Several previous studies have reported conflicting results in terms of QTc interval abnormalities in epilepsy: some reported a shortened QTc interval, while others mentioned a prolonged one [30] [31] [32] [33] . These differences might be explained by differences in the severity of epilepsy or prescribed medicines in each study [30] [31] [32] [33] . Although the patients with a J-wave-like ECG abnormality showed a shorter QTc than those without it in the present study, the precise mechanism involved is unclear. If the J-wave in these cases is associated with a repolarization abnormality, it might correlate with QTc interval. Haïssaguerre et al. reported that patients who were diagnosed with idiopathic ventricular fibrillation with early repolarization showed a shorter QTc interval than those without early repolarization [3] . The J-wave itself might be associated with a shorter QTc interval.
Limitations
Our study has several limitations. First, the number of patients was limited. We did not perform an active comparison of drugrefractory epilepsy and drug-responsive epilepsy. In this study, we evaluated patients with 12-lead ECG recordings and were taking AEDs. The number of 12-lead ECGs was limited. Therefore, this study was a retrospective analysis, and we could not evaluate the time interval that had elapsed between the most recent seizure and these ECG changes. We did not understand the reason for the low number of ECG recordings, although it might be that the study population was affected by selection bias. Second, only two of our included patients had both a pre-and post-medication ECG on file. The former was not available in most of the patients, so the influences of epilepsy itself versus those of the AEDs could not be separated. Third, because of the small number of subgroup patients, the effect of each AED could not be evaluated. Finally, genetic examinations, especially of sodium channel mutations, were not performed. We hope that these limitations will be overcome in future studies.
Conclusions
Brugada-type ST elevation and a J-wave-like ECG abnormality were observed in 12.5% and 29.2% of patients with epilepsy and those taking AEDs, rates that are higher than those in the general population. The presence of epilepsy and polytherapy with sodium channel-blocking AEDs may modulate ventricular depolarization and/or repolarization patterns and reveal Brugada-type ST elevation and/or a J-wave-like ECG abnormality.
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